Audeo Oncology (Audeo Oncology) Interest Expense : $0.00 Mil (TTM As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Audeo Oncology's interest expense for the three months ended in Sep. 2012 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Audeo Oncology's Operating Income for the three months ended in Sep. 2012 was $ -4.81 Mil. Audeo Oncology's Interest Expense for the three months ended in Sep. 2012 was $ 0.00 Mil. Audeo Oncology has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Audeo Oncology Interest Expense Historical Data

The historical data trend for Audeo Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology Interest Expense Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Interest Expense

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Interest Expense	-	-	-	-

Audeo Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Audeo Oncology (DELISTED:AURX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Audeo Oncology's Interest Expense for the three months ended in Sep. 2012 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2012 was $-4.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2012 was $0.00 Mil.

Audeo Oncology's Interest Coverage for the quarter that ended in Sep. 2012 is calculated as

Audeo Oncology had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.